---
title: "VK2735 in Chronic weight management: Diagnosis"
description: "Formulary evidence on VK2735 in Chronic weight management: Diagnosis. Topics: Body mass index categories for adults, Screening and confirmation of excess adiposity: ADA Standards of Care, Diagnosis of clinical obesity: Lancet Diabetes and Endocrinology Commission criteria, Complication-centric diagnosis: AACE algorithm, and 3 further topics. 7 evidence topics quoted from 9 sources."
canonical: "https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description/diagnosis"
published: "2026-11-15T21:45:47-05:00"
modified: "2026-11-15T21:45:47-05:00"
---

# VK2735 in Chronic weight management: Diagnosis

<a id="heading-2.2.1.5"></a>

## 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

### Body mass index categories for adults

| BMI category | BMI range (kg/m2) |
| --- | --- |
| Underweight | “Less than 18.5” |
| Healthy weight | “18.5 to less than 25” |
| Overweight | “25 to less than 30” |
| Class 1 obesity | “30 to less than 35” |
| Class 2 obesity | “35 to less than 40” |
| Class 3 obesity (severe obesity) | “40 or greater” |

Source: [CDC Adult BMI Categories (2024)](https://www.cdc.gov/bmi/adult-calculator/bmi-categories.html)

<a id="topic-2.2.1.5-2"></a>

### Screening and confirmation of excess adiposity: ADA Standards of Care

> “8.2a Screen for overweight and obesity using BMI annually. To confirm excess adiposity, additional assessments of body fat using anthropometric assessments (e.g., waist-to-hip ratio) or direct measurements (e.g., dual-energy X-ray absorptiometry, bioelectrical impedance analysis) could be considered where available/feasible.”
> “It is recommended that excess adiposity be confirmed by either direct measurement of body fat, where available, or at least one anthropometric criterion (e.g., waist circumference, waist-to-hip ratio, or waist-to-height ratio) in addition to BMI, using validated methods and cutoff points appropriate to age, sex, and ethnicity and particularly in individuals with BMI 25–34.9 kg/m2 and in certain populations (South Asian individuals), as these measurements better reflect metabolic disease”
> “Thus, although BMI is not a perfect measure of adiposity, it remains an acceptable measure for use by clinicians who may not have the resources to obtain additional measures of adiposity on all individuals.”

Source: [American Diabetes Association Professional Practice Committee (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12690172/)

<a id="topic-2.2.1.5-3"></a>

### Diagnosis of clinical obesity: Lancet Diabetes and Endocrinology Commission criteria

> “To mitigate risk of both overdiagnosis and underdiagnosis of obesity, excess adiposity should be confirmed by at least one other anthropometric criterion (eg, waist circumference) or by direct fat measurement when available. However, in people with substantially high BMI levels (ie, >40 kg/m2) excess adiposity can be pragmatically assumed.”
> “We recommend that BMI should be used only as a surrogate measure of health risk at a population level, for epidemiological studies, or for screening purposes, rather than as an individual measure of health.”
> “We defined 18 criteria for the diagnosis of clinical obesity in adults (range of consensus 90–100%; table 2), plus 13 criteria in children and adolescents (range of consensus 96–100%; table 2).”
> “A combination of an obesity phenotype with signs, symptoms, limitations of daily activities, or any combination of these.”

Source: [Rubino et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11870235/)

<a id="topic-2.2.1.5-4"></a>

### Complication-centric diagnosis: AACE algorithm

> “(3) diagnosis: anthropometric component, (4) diagnosis: clinical component”
> “Emphasis is placed on optimizing health rather than just weight reduction and achieving clinical goals other than a singular focus on body mass index (ie, complication-centric care).”

Source: [Nadolsky et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40956256/)

<a id="topic-2.2.1.5-5"></a>

### Waist circumference as a vital sign

> “We argue that BMI alone is not sufficient to properly assess or manage the cardiometabolic risk associated with increased adiposity in adults”
> “We recommend that health professionals are trained to properly perform this simple measurement and consider it as an important ‘vital sign’ in clinical practice.”

Source: [Ross et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7027970/)

<a id="topic-2.2.1.5-6"></a>

### Limitations of body mass index across populations

> “BMI does not measure body fat directly, nor does it provide information on body fat distribution”
> “Despite these limitations, BMI is a simple and inexpensive screening tool for conditions that may increase the risk of certain chronic diseases.”

Source: [Emmerich et al. (2024)](https://www.cdc.gov/nchs/products/databriefs/db508.htm)

> “In particular, research suggests that health risks may begin at a lower BMI among Asian people compared with other race and Hispanic-origin groups”
> “Additionally, research suggests that BMI overestimates adiposity (body fat) among Black people at a given BMI compared with others”

Source: [Fryar et al. (2026)](https://www.cdc.gov/nchs/data/hestat/hestat111.htm)

<a id="topic-2.2.1.5-7"></a>

### Early identification and assessment of complications by health practitioners

> “Health practitioners need to: routinely assess weight status and identify overweight and obesity early; provide evidence-based counselling on healthy diet, physical activity, sleep and other healthy behaviours to all; assess obesity-related complications, comorbidities, hypertension, diabetes, disability, mental health and other NCD risk factors”

Source: [WHO (2026)](https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight)

Additional sources: [Busetto et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38969880/)

## Related pages
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management.md)
- [VK2735 in Chronic weight management: Terms and abbreviations](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations.md)
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary.md)
- [VK2735 in Chronic weight management: Product information and disease description](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description.md)
- [VK2735 in Chronic weight management: Clinical evidence](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence.md)
- [VK2735 in Chronic weight management: Economic information and modeling report](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics.md)
- [VK2735 in Chronic weight management: References](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references.md)
